4IFH

Crystal structure of human insulin degrading enzyme (IDE) in complex with compound BDM44619


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.286 Å
  • R-Value Free: 0.224 
  • R-Value Work: 0.182 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in mice.

Deprez-Poulain, R.Hennuyer, N.Bosc, D.Liang, W.G.Enee, E.Marechal, X.Charton, J.Totobenazara, J.Berte, G.Jahklal, J.Verdelet, T.Dumont, J.Dassonneville, S.Woitrain, E.Gauriot, M.Paquet, C.Duplan, I.Hermant, P.Cantrelle, F.X.Sevin, E.Culot, M.Landry, V.Herledan, A.Piveteau, C.Lippens, G.Leroux, F.Tang, W.J.van Endert, P.Staels, B.Deprez, B.

(2015) Nat Commun 6: 8250-8250

  • DOI: 10.1038/ncomms9250
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Insulin-degrading enzyme (IDE) is a protease that cleaves insulin and other bioactive peptides such as amyloid-β. Knockout and genetic studies have linked IDE to Alzheimer's disease and type-2 diabetes. As the major insulin-degrading protease, IDE is ...

    Insulin-degrading enzyme (IDE) is a protease that cleaves insulin and other bioactive peptides such as amyloid-β. Knockout and genetic studies have linked IDE to Alzheimer's disease and type-2 diabetes. As the major insulin-degrading protease, IDE is a candidate drug target in diabetes. Here we have used kinetic target-guided synthesis to design the first catalytic site inhibitor of IDE suitable for in vivo studies (BDM44768). Crystallographic and small angle X-ray scattering analyses show that it locks IDE in a closed conformation. Among a panel of metalloproteases, BDM44768 selectively inhibits IDE. Acute treatment of mice with BDM44768 increases insulin signalling and surprisingly impairs glucose tolerance in an IDE-dependent manner. These results confirm that IDE is involved in pathways that modulate short-term glucose homeostasis, but casts doubt on the general usefulness of the inhibition of IDE catalytic activity to treat diabetes.


    Organizational Affiliation

    Institut Pasteur de Lille, Lille F-59000, France.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Insulin-degrading enzyme
A, B
990Homo sapiensMutation(s): 13 
Gene Names: IDE
EC: 3.4.24.56
Find proteins for P14735 (Homo sapiens)
Go to Gene View: IDE
Go to UniProtKB:  P14735
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
ZN
Query on ZN

Download SDF File 
Download CCD File 
A, B
ZINC ION
Zn
PTFCDOFLOPIGGS-UHFFFAOYSA-N
 Ligand Interaction
1EF
Query on 1EF

Download SDF File 
Download CCD File 
B
N-({1-[(2R)-4-(hydroxyamino)-1-(naphthalen-2-yl)-4-oxobutan-2-yl]-1H-1,2,3-triazol-4-yl}methyl)-4-methylbenzamide
C25 H25 N5 O3
QIIHKUBWBJHTFJ-HSZRJFAPSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.286 Å
  • R-Value Free: 0.224 
  • R-Value Work: 0.182 
  • Space Group: P 65
Unit Cell:
Length (Å)Angle (°)
a = 263.022α = 90.00
b = 263.022β = 90.00
c = 90.590γ = 120.00
Software Package:
Software NamePurpose
PHENIXrefinement
HKL-3000data reduction
HKL-3000data scaling
HKL-3000data collection
PHASERphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2013-12-18
    Type: Initial release
  • Version 1.1: 2015-10-28
    Type: Database references